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Background: Small studies have yielded divergent results for administration of granulocyte colony-stimulating factor (G-CSF) after acute myocardial infarction. Adequately powered studies involving patients with at least moderate left ventricular dysfunction are lacking.
Methods:
Patients with left ventricular ejection fraction less than 45% after anterior-wall myocardial infarction were treated with G-CSF (10 µg/kg daily for 4 days) or placebo. After initial randomization of 86 patients, 41 in the placebo group and 39 in the G-CSF group completed 6-month follow-up and underwent measurement of left ventricular ejection fraction by radionuclide angiography.
Results: Baseline and 6-week mean ejection fraction was similar for the G-CSF and placebo groups: 34.8% (95% confidence interval [CI] 32.6%-37.0%) v. 36.4% (95% CI 33.5%-39.2%) at baseline and 39.8% (95% CI 36.2%-43.4%) v. 43.1% (95% CI 39.2%-47.0%) at 6 weeks.
However, G-CSF therapy was associated with a lower ejection fraction at 6 cells, G-CSF modulates intracellular signalling cascades within cardiomyocytes and can activate neutrophils, and several trials have been stopped early as a result of excessive in-stent restenosis and acute coronary syndromes in patients with coronary artery disease. [7] [8] [9] [10] [11] Animal data have similarly yielded discordant results, depending on the dose and timing of G-CSF. 12 To clarify the role of G-CSF in promoting left ventricular recovery after acute myocardial infarction, we performed an adequately powered randomized clinical trial in patients with moderate left ventricular dysfunction following anteriorwall STEMI.
Methods
Study design and patients
The University of Ottawa Heart Institute regional STEMI program services a population of about 1.3 million residents in eastern Ontario. 13, 14 The CArdiovascular Percutaneous Intervention TriAL group's G-CSF for STEM cell mobilization post Myocardial Infarction (CAPITAL STEM MI, NCT00394498) trial was a prospective, randomized clinical study involving consecutive eligible patients referred for care between October 2005 and March 2010. Inclusion criteria specified presentation with anterior-wall STEMI with ejection fraction less than 45%. Reperfusion could be achieved by primary percutaneous coronary intervention (PCI) or thrombolysis followed by rescue or pharmacoinvasive PCI with insertion of 1 or more coronary stents. Exclusion criteria were prior STEMI, regional-wall motion abnormalities in non-infarct-related regions, prior coronary artery bypass grafting, severe valve disease (i.e., more than moderate), active infection requiring intravenous antibiotics, confirmed or possible pregnancy, enrolment in another clinical trial and left ventricular dysfunction with known or suspected nonischemic cause.
The study was double-blinded and placebocontrolled. Randomization was achieved by a computer-generated randomization sequence, with patient assignment determined by opening sealed opaque envelopes. Enrolment and randomization were performed by study staff, and blinding of patients and physicians was maintained by preparation of placebo in syringes packaged similarly to those containing G-CSF. The intervention consisted of G-CSF (Filgrastim, Amgen, Mississauga, Ont.) administered subcutaneously at a dose of 10 µg/kg daily for 4 days beginning on day 3 or 4 after STEMI. Adjuvant pharmacotherapy was administered at the discretion of the treating physician.
The study was approved by the University of Ottawa Heart Institute Human Research Ethics Board, and all patients provided written informed consent.
Outcome measures
We performed clinical follow-up at 6 weeks and 6 months. The primary outcome was left ventricular ejection fraction, as assessed by left ventricular radionuclide angiography at 6 months. Secondary end points were left ventricular ejection fraction at 6 weeks, change in ejection fraction over time and a composite of major adverse cardiac events at 6 months, including death, cerebrovascular accident (as diagnosed by a treating neurologist), targetvessel revascularization and severe heart failure requiring admission.
Left ventricular radionuclide angiography
Electrocardiogram-gated equilibrium blood pool images were obtained in 45°left anterior oblique views with a Cardial-Apex camera (GE). We calculated the left ventricular ejection fraction using the mean of 2 measurements for the enddiastolic and end-systolic counts. All measurements were performed by a single technologist, and images were processed using a standard software package (Xpert Workstation). Both the technologist and the reading physician (R.S.B.) remained blinded to the treatment assignment. More detailed protocols for blood counts and left ventricular diastolic function are available in Appendix 1 (available at www .cmaj .ca /lookup /suppl /doi :10.1503 /cmaj .140133 /-/DC1). in left ventricular ejection fraction, we used a mixedmodel repeated-measures analysis, with treatment group as the "between" factor (G-CSF v. placebo) and time as the "within" factor (baseline, 6 wk, 6 mo). To calculate sample size, we estimated that the left ventricular ejection fraction in the G-CSF group would be 4% higher than in the placebo group, on the basis of previous studies and consensus among the investigators regarding a minimal clinically important difference. Using an estimated standard deviation of 6% and a level of significance (α) of 0.05, we calculated a necessary sample size of 38 patients per group to have 80% power to detect a significant difference. We assumed that Research 5 patients would not complete the study because of death or drop-out, and therefore recruited 43 patients per group.
Statistical analysis
All analyses were performed using SAS software version 9.2 and Mix Meta-analysis version 1.7. Differences with a p value of 0.05 or less were considered significant. All imaging data were interpreted with blinding, and none of the interpreting physicians were aware of the treatment group.
Meta-analysis
We updated previous meta-analyses 5, 6 to include the results of the current study. The complete methods, described in detail previously, 15 can be reviewed in Appendix 1 (available at www .cmaj .ca /lookup /suppl /doi :10.1503 /cmaj .140133 /-/DC1).
Results
Population and baseline characteristics Eighty-six consecutive eligible patients were enrolled in the study ( Figure 1 ). A single patient in each group withdrew consent following randomization, and all data for these 2 patients were withdrawn from the analysis. Furthermore, before the 6-month follow-up, a single patient in each group died, and in the G-CSF group 1 patient was lost to follow-up and 1 patient underwent cardiac transplant. Accordingly, 41 patients in the placebo group and 39 patients in the G-CSF group completed 6-month followup and were included in the primary outcome analysis. As expected, baseline demographic characteristics, procedure-related variables and medical therapy were similar between the groups (Table 1) .
Effect of G-CSF on laboratory results and stem cell mobilization
Baseline hematologic values, specifically leukocyte counts, hemoglobin, platelet counts and components of the leukocyte count (lymphocytes, monocytes and neutrophils), were all similar between the 2 groups ( Table 2) . By day 4, treatment with G-CSF was associated with higher leukocyte counts (49.8 ± 12.8 × 10 9 /L v. 9.2 ± 2.7 × 10 9 /L, p < 0.001), and more CD34 Table 4 .
The secondary end point of a major adverse cardiac event by 6 months occurred in 8 patients (19%) in each group (Table 3) . Specifically, 1 death and 1 case requiring coronary artery bypass graft occurred in each group. Notably, rates of target-vessel revascularization were similar between the placebo and G-CSF groups (14% v. 12%). One patient in the G-CSF group underwent cardiac transplant at 4 months after infarction, with a 6-week ejection fraction of 14%.
Interpretation
This trial was designed to ensure adequate power in investigating the use of G-CSF in patients with moderate left ventricular dysfunction following anterior-wall myocardial infarction. Contrary to the primary hypothesis, G-CSF therapy resulted in lower left ventricular ejection fraction (by 5.7 percentage points) at 6-month follow-up. Furthermore, our updated meta-analysis involving 14 randomized studies suggested no benefit of G-CSF following acute myocardial infarction but provided no signal of increased major adverse cardiac events in patients receiving this therapy. Nonetheless, the significant negative effect of G-CSF on left ventricular ejection fraction observed in the current study raises concerns about the safety of this therapy for patients with moderate left ventricular dysfunction following myocardial infarction. Although no definite increase in major adverse cardiac events was observed, the current study and the associated meta-analysis remain underpowered, and followup to date has been inadequate to detect impor- Note: ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, G-CSF = granulocyte colony-stimulating factor, IQR = interquartile range, PCI = percutaneous coronary intervention, SD = standard deviation, TIMI = thrombolysis in myocardial infarction. *Unless otherwise stated.
tant differences in clinical outcomes that may result from lower left ventricular ejection fraction over the long term. As a result, ongoing studies with G-CSF for left ventricular recovery warrant careful long-term monitoring of ejection fraction and clinical outcomes to ensure safety. In addition to mobilization of progenitor cells, G-CSF has been shown to have pleiotropic effects following myocardial infarction. For example, reduction in myocyte apoptosis 16 and reductions in arrhythmias through upregulation of connexin 43 have been reported. 17 Thus, whereas mobilization of progenitor cells is one manner in which G-CSF may alter the myocardial healing process, pleiotropic effects may alter the expected response to therapy. In the current study, mobilization of progenitor cells did not correlate with left ventricular recovery, and the mechanisms by which G-CSF may have impaired systolic function remain unclear. However, G-CSF has been reported to have pro-inflammatory and thrombotic effects, both of which may contribute to impairment of left ventricular recovery. 18 Nonetheless, our results highlight the difficulty of translating findings from preclinical animal models into therapeutic practice and emphasize the need for welldesigned clinical trials.
A previous meta-analysis suggested that patients with left ventricular ejection fraction less than 50% benefited from administration of G-CSF after myocardial infarction. 5 Given the results of our study, we updated the meta-analysis to include 14 randomized trials with a total of 566 patients (see Appendix 2, available at www .cmaj .ca /lookup /suppl /doi :10.1503 /cmaj .140133 /-/DC1). Our updated analysis showed no effect of G-CSF on left ventricular ejection fraction (Appendix 2, Figure 2A , mean difference 2.0 [95% CI -0.9 to 4.8] percentage points, p = 0.2). In a prespecified secondary analysis, including only studies with baseline left ventricular ejection fraction less than 45%, there was no benefit of G-CSF for this subset of patients when the findings of the current study were factored in (Appendix 2, Figure 2B , mean difference 0.7 [95% CI -2.5 to 4.0] percentage points, p = 0.7). Overall, in the 12 studies reporting major adverse cardiac events, no difference was observed between G-CSF and placebo (relative risk 0.97, 95% CI 0.73 to 1.30, p = 0.9; Appendix 2, Figure 3) . Notably, only 5 of the 14 clinical trials published to date have reported lower left ventricular ejection fraction with G-CSF therapy, the current study being the first with a statistically significant result. Although it may be tempting to dismiss our finding as an outlier, there are several potential explanations. First, the baseline ejection fraction in our study was about 35%, considerably lower than in other reports. Indeed, the only other study involving patients with moderate left ventricular dysfunction reported that left ventricular ejection fraction was 3.0 percentage points lower with G-CSF. 19 The only other large study with adequate power 20 enrolled patients with nearnormal left ventricular ejection fraction and reported no difference in left ventricular recovery. Thus, it is possible that our trial is the first to detect possible harm, given the relatively mild degree of left ventricular dysfunction and the lack of power in previous studies. Notably, 3 other trials of G-CSF in patients with coronary artery disease were stopped early because of safety concerns: 1 trial for increased risk of in-stent restenosis 8 and 2 trials for increased risk of acute coronary syndromes. 10, 11 This situation is particularly noteworthy given that research on G-CSF for patients with coronary disease or chronic left ventricular dysfunction (or both) is continuing. Heart failure requiring admission 3 (7) 1 (2) > 0.9
Note: CI = con dence interval, G-CSF = granulocyte colony-stimulating factor. A second possible explanation relates to the timing of G-CSF administration. In the current study, G-CSF therapy was not initiated until day 3 or 4 after infarction. Interestingly, positive data from animal studies used protocols with G-CSF administration before or at the time of infarct. [21] [22] [23] [24] By comparison, in a study of immediate versus delayed (5 d postinfarct) G-CSF therapy, delayed therapy was associated with a 24% increase in end diastolic volume and a significant increase in infarct mass relative to placebo. 12 Similarly, a previous meta-analysis of clinical studies suggested benefit with early (< 37 h) initiation of G-CSF therapy. 5 Congruent with this hypothesis is the observation that the largest benefit reported to date in terms of left ventricular recovery occurred in a trial in which therapy was administered only 1.5 hours from the time of reperfusion. 25 It is tempting to hypothesize that timing of G-CSF therapy is critical and that a lack of benefit may result from delayed initiation of therapy. Nonetheless, although methodologic and population differences may partly explain the difference, our study raises substantial concerns about the use of G-CSF in patients with moderate left ventricular dysfunction following myocardial infarction.
Limitations
This study had some limitations. We used a surrogate marker (final left ventricular ejection fraction) as our primary outcome. Although the study was not powered to detect differences in clinical events, follow-up left ventricular ejection fraction has been validated, both before and after PCI became available, as a powerful predictor of long-term mortality. 26 As well, 4 patients in the G-CSF group and 2 patients in the placebo group did not undergo 26-week assessment of left ventricular ejection fraction, making postrandomization dropout a potential source of bias in this relatively small study. Interestingly, in the placebo group, left ventricular recovery was robust, at 9 percentage points over the 6-month follow-up period, more than double that predicted on the basis of previous studies. This observation is critical for future studies of novel therapies targeting left ventricular recovery, as larger sample sizes will ultimately be needed to demonstrate efficacy. Finally, the majority of patients recruited for this study were men, which limits the generalizability of our findings, given that important sex-specific differences in remodelling of the myocardium after myocardial infarction have been reported. 27 
Conclusion
Among patients with moderate left ventricular dysfunction after anterior wall infarction, delayed G-CSF therapy was associated with lower 6-month left ventricular ejection fraction but not with increased risk of major adverse cardiac events. Future studies of G-CSF therapy for patients with left ventricular dysfunction should be monitored closely for safety.
